Medigene AG: Dr. Anthony Man appointed to Supervisory Board
Planegg/Martinsried (16.12.2020) - The Executive Management Board and the Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, following today's Annual General Meeting (AGM) of shareholders, welcomes Dr. Anthony Man as new member to the Supervisory Board and would also like to thank retiring members, Prof. Horst Domdey and Dr. Yita Lee, for their years of unerring support to the company.
Dr. Man, Global Clinical Development Head, Communicable Diseases, Global Health Development Unit at Novartis Pharma AG in Basel, Switzerland, is a medically qualified professional with many years of international drug development experience in the pharmaceutical and biotechnology industry. This includes previous significant roles in the development and approval of around 30 different new drugs in multiple therapeutic areas (including oncology) and senior executive management responsibilities in companies such as Novartis and Roche, among others. He commented: "I am delighted to be joining the Medigene Supervisory Board and believe the depth of my industry and scientific experience will complement the team. I look forward to working with the other members and the management team to advance the Company in the coming years."
Dr. Gerd Zettlmeissl, Chairman of Medigene's Supervisory Board: "Dr. Anthony Man will support Medigene to further develop its standing in the field of innovative T cell-based immunotherapies with his significant international experience in the development and commercialization of biopharmaceutical therapies and his extensive knowledge of the pharmaceutical industry and the capital markets. On behalf of the Board, I thank the shareholders of Medigene AG for their vote of confidence. Prof. Domdey and Dr. Lee have each served as members of the Supervisory Board since 2013. We are most grateful for their contributions to Medigene and wish them well in the future."
--- end of press release ---
Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Dr. Gary Waanders, Dr. Anna Niedl
Phone: +49 89 2000 3333 01
Phone: +44 7483 284 853
emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate
Currently there is a rather positive sentiment for Medigene AG with 5 Buy predictions and 1 Sell predictions.
With a target price of €8.00 there is potential for a 106.986% increase which would mean more than doubling the current price of €3.87 for Medigene AG.